Work

Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models

Year: 2017

Type: article

Abstract: population. We test the effect of targeting this receptor using the monoclonal antibody TRC105, and find that in AML, TRC105 prevented the engraftment of primary AML blasts and inhibited leukemia progression following disease establishment, but in B-ALL, TRC105 alone was ineffective due to the shedding of soluble CD105. However, in both B-ALL and AML, TRC105 synergized with reduced intensity myeloablation to inhibit leukemogenesis, indicating that TRC105 may represent a novel therapeutic option for B-ALL and AML.

Source: Blood

DOI: 10.1182/blood-2017-01-763581